Cipla soars on completing Phase-3 clinical study for generic version of GSK's Advair Diskus

03 Apr 2020 Evaluate
Cipla is currently trading at Rs. 439.25, up by 25.70 points or 6.21% from its previous closing of Rs. 413.55 on the BSE.

The scrip opened at Rs. 425.00 and has touched a high and low of Rs. 442.50 and Rs. 417.10 respectively. So far 118869 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 447.85 and Rs. 391.35 respectively. The current market cap of the company is Rs. 35059.14 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.

Cipla has successful completed Phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder (100/50 mcg). Fluticasone propionate and salmeterol inhalation powder 100/50 mcg, 250/50 mcg and 500/50 mcg are generic versions of GSK’s Advair Diskus.

The product is indicated to treat asthma in patients 4 years and older as a twice-daily prescription medicine and in long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups. The Phase-3 study, successfully completed in the first attempt, was conducted over a period of 15 months at over 100 sites in the US enrolling 1400 asthma patients.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1347.70 -6.55 (-0.48%)
23-Apr-2024 15:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1483.75
Dr. Reddys Lab 5947.30
Cipla 1347.70
Zydus Lifesciences 958.90
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.